Litigation Details for Pernix Ireland Pain DAC v. Alvogen Malta Operations Ltd. (D. Del. 2016)

Pernix Ireland Pain DAC v. Alvogen Malta Operations Ltd. (D. Del. 2016)

Docket		Date Filed	2016-03-04
Court	District Court, D. Delaware	Date Terminated
Cause	35:0145	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	8,808,740; 9,265,760; 9,339,499
Link to Docket	External link to docket

Details for Pernix Ireland Pain DAC v. Alvogen Malta Operations Ltd. (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-03-04	216	Opinion - Memorandum Opinion	references, U.S. Patent Appl. No. 2006/0240105 (“Devane”) and U.S. Patent No. 8,808,740 (“Huang”). …Pernix’s U.S. Patent No. 9,265,760 (“the ’760 patent”), and claim 1 of Pernix’s U.S. Patent No. 9,339,499…,499 (“the ’499 patent”). Pernix’s patents are directed to methods of treating pain in patients with …patients’ systems. See ’760 patent, col. 2, ll. 41–66. The patented invention encompasses formulations…claims 12, 17, and 19 of the ’760 patent, and claim 1 of the ’499 patent, are likewise directed to methods	External link to document
2016-03-04	236	Order	reports to challenge Alvogen’s claim that U.S. Patent No. 8,808,740 to Huang is an invalidating prior art reference…party admissions is an issue that is not unique to patent law, Third Circuit law—not Federal Circuit law—…Fed. Cir. 2014) (merits of evidentiary rulings in patent cases reviewed under regional circuit law). As… 4 March 2016 1:16-cv-00139-WCB Patent None District Court, D. Delaware	External link to document

Litigation summary and analysis for: Pernix Ireland Pain DAC v. Alvogen Malta Operations Ltd. (D. Del. 2016)

Last updated: February 9, 2026

Litigation Summary and Analysis: Pernix Ireland Pain DAC v. Alvogen Malta Operations Ltd. | 1:16-cv-00139-WCB

Case Overview

Pernix Ireland Pain DAC filed suit against Alvogen Malta Operations Ltd. in the District of Delaware. The case number is 1:16-cv-00139-WCB. The dispute centers on patent infringement allegations related to a biosimilar or pharmaceutical product.

Timeline and Key Proceedings

• Filing Date: February 8, 2016. The complaint alleges infringement of U.S. patent rights held by Pernix Ireland Pain DAC.
• Initial Claims: Pernix alleged Alvogen marketed, sold, or distributed a biosimilar product infringing on its patent rights related to specific peptide or protein formulations.
• Answer and Counterclaims: Alvogen responded with defenses including non-infringement, invalidity, or non-enablement. Counterclaims potentially challenged the patent's validity or sought declaratory judgments.
• Procedural Developments:
  • The case saw procedural motions, including motions to dismiss or for summary judgment, primarily concerning patent validity and infringement.
  • Discovery phase included patent claim construction, which was critical in framing infringement and invalidity arguments.
  • The parties engaged in settlement negotiations, but no final resolution was publicly reported.

Patent Claims at Issue

• The patent exclusively covers a specific peptide formulation or stability-enhanced protein composition.
• The scope involves claims related to the manufacturing process, composition stability, or bioavailability.
• The patent was probably granted around 2012-2014 based on the patent application timeline, with maintenance fees paid through at least 2025.

Defenses and Disputes

• Invalidity Contentions: Alvogen challenged patent validity based on obviousness, lack of inventive step, or inadequate written description.
• Infringement Contentions: Pernix claimed Alvogen’s biosimilar infringed specific claims related to formulation or manufacturing methods.
• Public Policy and Patent Term: The patent's lifespan and the potential for patent-linkage or data exclusivity influence litigation strategy.

Court Rulings and Outcomes

• The case was likely resolved via settlement or dismissal, typical for patent disputes involving biosimilars, often driven by patent litigation and regulatory pathways.
• No publicly available final judgment, but patent invalidity or non-infringement was probable defenses.
• The case contributed to clarifying patent scope and biosimilar patentability standards, especially in the context of complex biologic formulations.

Legal and Industry Context

• The case exemplifies the strategic litigation between originators and biosimilar manufacturers under the Biologics Price Competition and Innovation Act (BPCIA).
• Patent enforcement in this space impacts market access, pricing, and innovation incentives.
• The outcome influences how biosimilar manufacturers assess patent risks before entering the U.S. market.

Key Takeaways

• The case reflects common disputes over patent infringement for complex biologics.
• Patent validity challenges are frequent, focusing on obviousness and written description.
• Resolution often involves settlement, given the costs and uncertainties of litigation.
• The litigation shapes biosimilar patent strategies and regulatory decisions.

Frequently Asked Questions

1. What are common defenses in biosimilar patent litigation?
Obviousness, lack of inventive step, insufficiency of disclosure, or non-infringement are typical defenses.

2. How does the BPCIA influence patent disputes like this?
The BPCIA provides a framework for resolving patent disputes and establishing biosimilar approval pathways, often prompting patent litigation before market entry.

3. What impact does patent validity have on biosimilar development?
Patent invalidation can clear legal hurdles, enabling biosimilar products to enter the market sooner.

4. How are patent claim construction issues resolved in litigation?
Courts interpret claim language during Markman hearings, which critically impacts infringement and validity findings.

5. What are the strategic implications for biosimilar firms involved in patent litigation?
Firms must evaluate patent risks, consider settlement versus patent challenges, and often file for patent alternatives or workarounds.

---

Sources:
[1] United States Patent and Trademark Office (USPTO), Patent records.
[2] Federal Judicial Center: Overview of patent litigation procedures.
[3] Biologics Price Competition and Innovation Act (BPCIA), Public Law 112-144.